HIV Infections Clinical Trial
Official title:
A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine
Verified date | April 2011 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC).
Status | Completed |
Enrollment | 0 |
Est. completion date | April 2003 |
Est. primary completion date | April 2003 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria Patients may be eligible for this study if they: - Have a viral load of 2,000 or more copies/ml and a CD4 cell count of 100 or more cells/mm3 (or 75 or more cells/mm3 with no prior history of AIDS-defining diagnosis) within 2 weeks before randomization. - Are at least 16 years old. - Have signed consent of parent or guardian if under 18 years of age. - Are willing to use effective barrier methods of birth control. - Are available for follow-up for at least 52 weeks. Exclusion Criteria Patients will not be eligible for this study if they: - Have had anti-HIV treatment within 30 days before screening. - Have a recently diagnosed HIV-related infection. - Have any medical condition requiring treatment at enrollment. - Have recently become HIV infected. - Have acute hepatitis within 30 days of study entry. Certain patients with chronic hepatitis will be eligible. - Expect to need or have taken drugs with myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic potential within 3 months before study. Expect to need methadone, ribavirin/interferons, neurotoxic drugs or drugs that affect CYP3A4. - Abuse alcohol or drugs. - Have severe diarrhea within 30 days before study entry. - Are pregnant or breast-feeding. - Have a history of hemophilia. - Have a history of bilateral peripheral neuropathy. - Cannot take medicines by mouth. - Have any other conditions that the doctor thinks would interfere with the study. |
Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | AKH Wien | Wien | |
Austria | Pulmologisches Zentrum Der Stadt Wien | Wien | |
Belgium | CHU Saint Pierre | Brussels | |
Belgium | UZ Gasthuisberg | Leuven | |
Canada | Univ of Alberta/Division of Inf Dis/Dept of Med | Edmonton | Alberta |
Canada | McMaster Univ Med Ctr | Hamilton | Ontario |
Canada | Gary Rubin | Toronto | Ontario |
Canada | Univ of British Columbia | Vancouver | British Columbia |
Chile | Fundacion Arriaran | Santiago | |
Chile | Hosp Clinico de La Pontificia Universidad Catolica de Chile | Santiago | |
Chile | Hosp Sotero de Rio | Santiago | |
Chile | Servicio de Dermatologia-Hosp del Salvador | Santiago | |
Costa Rica | SEMECO | San Jose | |
France | Hopital Hotel Dieu de Lyon | Lyon | |
France | CHU De Bicetre | Paris | |
France | Hopital Cochin - Port Royal | Paris | |
France | Services des Maladies Infectieuses | Paris Cedex 12 | |
France | Hospital Gustave Dron | Tourcoing | |
Germany | Rheinische Friedrich Wilhelms Universitaet Medizinische | Bonn | |
Germany | Univ Zu Koeln | Koeln | |
Guatemala | Hosp General San Juan de Dios | Guatemala | |
Guatemala | Hosp Roosevelt Chief Infectious Diseases Unit | Guatemala | |
Hungary | Saint Laszlo Hosp | Budapest | |
Israel | Kaplan Med Ctr | Rehovot | |
Italy | Ospedale S Orsola | Bologna | |
Italy | Immunoligia Universita Cagliari | Cagliari | |
Italy | Ospedale Luigi Sacco Cargnel | Milano | |
Italy | Ospedale S Raffaele | Milano | |
Italy | Ospedale degli Infermi | Rimini | |
Italy | Cat All Immun Clin | Roma | |
Italy | Ospedale Amedeo de Savoia | Torino | |
Italy | Ospedale Amedeo di Savoia | Torino | |
Malaysia | Hosp Kuala Lumpur | Kuala Lumpur | |
Malaysia | Univ of Malaya Med Ctr | Kuala Lumpur | |
Panama | Consultorio Royal Ctr | Panama | |
Peru | Hosp Edgardo Rebagliati | Lima | |
Peru | Hosp Guillermo Almenara-Medicina 1 | Lima | |
Peru | Hosp Nacional Arzobispo Loayza-PROCETS | Lima | |
Peru | Hosp Nacional Cayetano Heredia | Lima | |
Peru | Hosp Nacional dos de Mayo | Lima | |
Portugal | Hosp De Santa Maria | Lisboa | |
Portugal | Hosp De Sao Joao | Porto | |
Puerto Rico | Clinical Research Puerto Rico Inc | San Juan | |
Puerto Rico | San Juan VAMC | San Juan | |
Russian Federation | Federal AIDS Ctr | Moscow | |
Russian Federation | Infectious Hosp 30 | St Petersburg | |
Russian Federation | Ust Izhora Fed Infectious Hosp | St Petersburg | |
South Africa | Brooklyn Med Ctr | Cape Town | |
South Africa | Tygerberg Hosp | Cape Town | |
South Africa | Chris Hani Baragwanath Hosp | Johannesburg | |
South Africa | Toga Lab | Johannesburg | |
Spain | Hosp Clinic | Barcelona | |
Spain | Hosp Germans Trias I Pujol | Barcelona | |
Spain | Hosp de Basurto / Enfermedades Infecciosas | Bilboa | |
Spain | Hosp Reina Sofia | Cordoba | |
Spain | Hosp Carlos III | Madrid | |
Spain | Hosp Ramon y Cajal | Madris | |
Spain | Hosp Nuestra Senora de Covadonga | Oviedo | |
Spain | Hosp Virgen Del Rocio | Sevilla | |
Switzerland | Universitatsspital Zurich | Zurich | |
Thailand | Rajavithi Hosp | Bangkok | |
Thailand | Ramathibodi Hosp | Bangkok | |
Thailand | Siriraj Hosp / Mahidol Univ | Bangkok | |
Thailand | Vajira Hosp | Bangkok | |
Thailand | Chiangmai Univ | Chiang Mai | |
United Kingdom | King's College Hosp | Cambewell | |
United Kingdom | Saint James Hosp | Dublin | |
United Kingdom | Royal Free Hosp | London | |
United States | Univ of NM | Albuquerque | New Mexico |
United States | Univ of Michigan Hospitals and Health Ctrs | Ann Arbor | Michigan |
United States | Emory Univ | Atlanta | Georgia |
United States | The CORE Ctr | Chicago | Illinois |
United States | Ohio State Univ Hosp | Columbus | Ohio |
United States | Oaklawn Physicians Group | Dallas | Texas |
United States | Duke Univ Med Ctr / Infectious Disease Clinic | Durham | North Carolina |
United States | North Broward Hosp District / HIV Clinical Research | Fort Lauderdale | Florida |
United States | Associates in Research | Fort Myers | Florida |
United States | Tarrant County Infectious Diseases Associates | Fort Worth | Texas |
United States | Montrose Clinic | Houston | Texas |
United States | Jemsek Clinic | Huntersville | North Carolina |
United States | Univ of Southern California | Los Angeles | California |
United States | Methodist Healthcare | Memphis | Tennessee |
United States | Steinhart Medical Associates | Miami | Florida |
United States | Robert Wood Johnson Med School/UMDNJ | New Brunswick | New Jersey |
United States | UMDNJ - New Jersey Med School | Newark | New Jersey |
United States | Univ of Nebraska Medical Ctr | Omaha | Nebraska |
United States | Philadelphia FIGHT | Philadelphia | Pennsylvania |
United States | Phoenix Body Positive | Phoenix | Arizona |
United States | Saint Francis Mem Hosp / HIV Care Unit | San Francisco | California |
United States | ID Care Inc | Somerville | New Jersey |
United States | Washington Univ School of Medicine | St Louis | Missouri |
United States | Saint Josephs Comprehensive Research Institute | Tampa | Florida |
United States | Dr Bruce Rashbaum | Washington | District of Columbia |
United States | Dupont Circle Physicians Group | Washington | District of Columbia |
United States | Julio Arroyo | West Columbia | South Carolina |
United States | Univ of Kansas School of Medicine | Wichita | Kansas |
Venezuela | Hosp U de Caracas / Ciudad | Caracas | |
Venezuela | Hosp Vargas de Caracas | Caracas | |
Venezuela | Hosp Dr Domingo Luciani | Miranda |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Venezuela, Austria, Belgium, Canada, Chile, Costa Rica, France, Germany, Guatemala, Hungary, Israel, Italy, Malaysia, Panama, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Switzerland, Thailand, United Kingdom,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |